HH1 is caused by pathogenic variants in the ANOS1 gene located on the X chromosome. ANOS1 encodes anosmin-1, an extracellular matrix protein involved in the migration of GnRH neurons from the olfactory placode to the hypothalamic region during embryonic development. Disruption of this protein leads to failure of GnRH neuron migration, impairing hypothalamic GnRH secretion and the downstream reproductive hormone cascade. The condition follows an X-linked inheritance pattern, meaning the disease-causing variant is carried on the X chromosome. Because males possess only one X chromosome, a single pathogenic ANOS1 variant is sufficient to produce the full phenotype in males. Females carrying one pathogenic ANOS1 variant may have variable or absent phenotypic expression. ClinGen has classified the ANOS1 gene-disease relationship as DEFINITIVE, reflecting strong genetic evidence. According to GeneReviews, no single type of pathogenic variant in IGD-related genes is associated with a phenotype exclusive to a particular variant class, and variant interpretation requires consideration of clinical context.

According to GeneReviews, HH1 should be suspected when individuals present with absent or partial puberty in adolescence, low serum testosterone or estradiol, or findings of incomplete sexual maturation. In infant males, microphallus and cryptorchidism may raise early diagnostic suspicion. GeneReviews describes the diagnostic workup as encompassing biochemical measurement of serum concentrations of LH, FSH, total testosterone in males, and estradiol in females. A central diagnostic challenge is distinguishing isolated GnRH deficiency from secondary or syndromic causes of hypogonadotropic hypogonadism, such as pituitary lesions or constitutional delay of puberty; the GeneReviews differential diagnosis framework addresses this systematically. The concurrent presence of anosmia or hyposmia alongside gonadotropin deficiency, assessable through formal olfactory testing, supports the Kallmann syndrome subtype of IGD specifically. Molecular genetic testing of the ANOS1 gene may establish a definitive diagnosis in individuals with an X-linked family history pattern. GeneReviews notes that genetic diagnosis is particularly useful for reproductive planning and counseling in affected families. No structured, formal diagnostic criteria beyond these clinical and biochemical parameters are specified in this packet.

No FDA-approved treatments are certified in this packet for HH1. GeneReviews describes that clinical management of isolated GnRH deficiency is oriented toward addressing the consequences of sex hormone deficiency across the lifespan. According to GeneReviews, an expert European consensus statement on the management of IGD has been published and informs clinical practice. GeneReviews notes that for males, available clinical options have historically included sex steroids, gonadotropins, and pulsatile GnRH administration, with the choice among these determined by the treatment goals, which may include induction of pubertal development, maintenance of sex hormone levels, or facilitation of fertility. For females, analogous hormone replacement and fertility-directed approaches are described in the GeneReviews framework. GeneReviews also notes that children of both sexes with findings suggestive of IGD undergo periodic assessment of sexual maturation through Tanner staging, measurement of serum LH, FSH, and sex steroid concentrations, and bone age determinations as part of clinical follow-up. Certified approved treatment coverage beyond clinical practice descriptions is not established in this packet.

A formal natural history entry is not populated in this packet for HH1. GeneReviews describes that most individuals with isolated GnRH deficiency are identified at the time of expected puberty, though suggestive clinical features including microphallus or cryptorchidism may be present from infancy. GeneReviews documents that the reproductive phenotype is variable in severity across individuals, even among those carrying the same causative gene, suggesting that other genetic or environmental modifiers influence expression. Notably, GeneReviews describes that a subset of individuals experience spontaneous reversal of the hormone deficiency over time, indicating that the condition is not uniformly permanent. Ongoing clinical monitoring of serum sex steroid levels is part of established clinical practice for this condition. The impact on fertility depends on the degree of gonadotropin deficiency and the response to therapy. The presence or absence of anosmia does not appear to reliably predict reproductive prognosis based on available GeneReviews data. Overall long-term outcomes are substantially shaped by the completeness and timing of hormonal management.

Four clinical trials are registered for this condition in this packet. NCT01500447, titled “Inherited Reproductive Disorders,” is in a recruiting status, sponsored by the National Institute of Environmental Health Sciences (NIEHS), with no phase designation listed. NCT04733274, titled “Patient and Healthcare Professional Views on Genetic/Genomic,” is active but not recruiting, sponsored by Boston College, and focuses on perspectives related to genetic testing in reproductive contexts. NCT04463316, titled “GROWing Up With Rare GENEtic Syndromes,” is recruiting, sponsored by Dr. Laura C. G. de Graaff-Herder, and encompasses rare genetic syndromes affecting development. NCT01601171, titled “Genetics of Reproductive Disorders (Including Kallmann Syndrome),” is recruiting at Centre Hospitalier Universitaire Vaudois and focuses directly on the genetic characterization of HH1 and related conditions. The trial portfolio reflects ongoing natural history research, genetic data collection, and patient experience inquiry in this area. GeneReviews notes that ClinicalTrials.gov and the EU Clinical Trials Register serve as resources for identifying active studies.